Daily Stock Analysis, ARNA, Arena Pharmaceuticals Inc, priceseries

Arena Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
41.53
Close
40.85
High
42.20
Low
40.80
Previous Close
41.21
Daily Price Gain
-0.36
YTD High
42.74
YTD High Date
Feb 20, 2018
YTD Low
33.03
YTD Low Date
Jan 16, 2018
YTD Price Change
4.64
YTD Gain
12.81%
52 Week High
42.74
52 Week High Date
Feb 20, 2018
52 Week Low
1.13
52 Week Low Date
May 18, 2017
52 Week Price Change
39.43
52 Week Gain
2776.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 26. 2017
15.08
Jul 27. 2017
23.58
22 Trading Days
56.34%
Link
LONG
Sep 6. 2017
23.02
Sep 26. 2017
24.75
14 Trading Days
7.53%
Link
LONG
Nov 21. 2017
27.23
Dec 14. 2017
29.98
16 Trading Days
10.10%
Link
LONG
Dec 21. 2017
31.60
Jan 11. 2018
36.45
13 Trading Days
15.36%
Link
Company Information
Stock Symbol
ARNA
Exchange
NasdaqGS
Company URL
http://www.arenapharm.com
Company Phone
858-453-7200
CEO
Amit D. Munshi
Headquarters
California
Business Address
6154 NANCY RIDGE DRIVE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001080709
About

Arena Pharmaceuticals, Inc. is a biopharmaceutical company engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers a range of drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.

Description

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company's proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.